Mount Sinai School of Medicine
Alzheimer's Disease Research Center
Clinical Trials Information
| home | faq | contact us | mailing list |
Risperidone
Antipsychotic Discontinuation in Alzheimer's Disease
| Status: | Active and Recruiting |
| Eligible Population(s): | Alzheimer's Disease |
| GCO Number: | 06-0930 IRB approved through 08/31/2009 |
| Principal Investigator: | Corbett Schimming, MD |
| Study Coordinator: | Andrew Vigario |
We are looking for volunteers to participate in a research study that uses risperidone, which is an FDA-approved antipsychotic drug, in the current study as an experimental treatment for people with Alzheimer's disease (AD), who suffer from hallucinations, delusions, agitation and/or aggression. Risperidone is not a treatment for memory difficulties, but rather is being studied in this trial to see if it will improve behavioral difficulties associated with AD. This study continues over a period of 48 weeks. All participants will be carefully monitored at the research clinic throughout the study.
Participants are eligible to participate if:
- they are between 40-95 years of age
- have a diagnosis of probable AD
- have a Mini-Mental State Examination (MMSE) score between 5-26 (at the time of the screening visit)
- and have a caregiver who is able to attend all study visits.
For more information
If you would like a coordinator to contact you regarding Risperidone, please complete the form below.